C-List & Commercial Catalog Masterclass: Executive Interview on Huiminbao with Dr. Wanyan Ruiyun
Fudan expert shares insights on China’s first national negotiation for the commercial drug list—and its potential to reshape Huiminbao, influence drug pricing, accelerate insurance innovation, and transform drug distribution systems nationwide.
Not yet a member?
Access360 membership provides structured intelligence on China’s evolving health policy, coverage, and financing system, with member briefings, archive access, and opportunities to submit questions on published analyses.
Explore Membership